Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
A study out of China found most patients biopsied for prostate lesions did not have clinically significant cancer, calling the clinical ranking systems into question.
PET/CT imaging in these patients increases overall survival depending on the cancer’s stage, with those diagnosed with stage 3A and 3B NSCLC appearing to benefit the most from the exam.
This week in AJR, experts shared how they were able to reduce FDG PET scan acquisition times by 33%, thus reducing the amount of total radiation exposure to more vulnerable pediatric patients.
The Society of Nuclear Medicine and Molecular Imaging has chosen its 2022 Image of the Year, and it’s one that is sure to interest anyone in the field of cardiac imaging.
Salvage radiation therapy guidelines for patients with prostate cancer recurrence need to be updated to include findings identified on PSMA PET, according to new research shared at SNMMI’s annual conference this week.
“High-quality artificial intelligence-generated images preserve vital information from raw PET images without the additional radiation exposure from CT scans,” experts involved in the study explained.
Hybrid PET/CT enhanced with intravenous CT contrast deserves wider acceptance and adoption, as diagnostically optimized CT can complement PET—and vice versa—for a variety of potential indications. That’s one opinion on the matter.
For 45% to 47% of patients who were deemed negative after conventional baseline scans, the use of the radiohybrid imaging agent resulted in at least one true positive PET finding